Latest News

Opsona Therapeutics Limited raises €33 million Series C equity financing to advance clinical development of its lead product OPN-305.

April 29th, 2013, Dublin, Ireland – Opsona Therapeutics Limited, the innate immune drug development company, today announced that it has raised €33 million (US $43 million) in a Series C financing. The participants in this Series C financing include existing investors, Novartis Venture Fund, Fountain Healthcare Partners, Roche Venture Fund and Seroba-Kernel Life Sciences. The...


Seroba Kernel to Sponsor Major European Medtech Conference.

Seroba Kernel is delighted to announce that it is sponsoring the upcoming IN3 European Medtech Conference. It will be held in Dublin this coming April 16th-18th 2013.  As Ireland is home to one of the largest medical device clusters in Europe, we think Dublin is a great location in which to hold a truly Pan-European medtech meeting. This is the first such meeting in Ireland and we...


Apica Publishes in European Journal of Cardio-Thoracic Surgery.

5 April 2013 Dublin. Leading International clinicians have published the first paper on the clinical use of Seroba Kernel's investee company, Apica Cardiovascular's Access and Closure Device to deliver aortic valves through the apex of the heart. The paper, published in the Journal of Cardio-Thoracic Surgery (April 2013), was titled 'First-in-man evaluation of the...


< back to home page